# Transition Bio

**Canonical:** https://apis.io/providers/transition-bio/  
**Website:** https://transitionbio.com/  
**APIs profiled:** 0

Transition Bio is a preclinical drug discovery company built on biomolecular condensate science, operating as a joint spin-out of the University of Cambridge and Harvard University with sites in Cambridge, Massachusetts and Cambridge, United Kingdom. The company combines droplet-microfluidics high-throughput molecular screening with a machine learning engine to identify and optimize small molecules that modulate intrinsically disordered proteins and the condensates they form, an approach the company has described as its Condensomics platform. It was seeded in November 2020 and closed a $50 million Series A in June 2022 led by Northpond Ventures with Taiho Ventures, Bristol Myers Squibb and Magnetic Ventures participating, and in November 2025 announced a collaboration with Voyager Therapeutics on small molecules targeting TDP-43 in ALS and frontotemporal dementia. Transition Bio is a therapeutics developer rather than a software or data vendor: it publishes no developer portal, no API documentation and no machine-readable API contract on any host it controls.

## Kin Score — 5.1 / 100 (minimal)

Scored 2026-09-02 under rubric 0.18.0. Trend: flat (+0.0 from 5.1).

| Facet | Score |
|---|---|
| Discoverability | 50.0 |
| Contract Quality | 0.0 |
| Governance | 0.0 |
| Contract Governance | 0.0 |
| Operational Transparency | 2.6 |
| Developer Ergonomics | 7.1 |
| Commercial Clarity | 0.0 |
| Access Clarity | 0.0 |

Regulatory layer — **Health**: 7.5 (matched via tags).

## Agent readiness — 0.0 (human-only)

| Dimension | Value |
|---|---|
| Spec Presence | no |
| Agentic Access | no |
| Reversibility Documented | no |
| MCP Server | no |
| Auth Clarity | no |
| Idempotency | no |
| Error Semantics | no |
| OpenAPI Examples | no |
| Rate Limit Signal | no |
| Event Surface Described | no |
| Agent Skills | no |
| Well Known Catalog | no |
| Consent Identity | no |
| Agent Card | no |
| Dry Run Mode | no |
| Delegated Identity | no |
| Protected Resource Metadata | no |
| Dynamic Client Registration | no |
| Agentic Commerce | no |

## Access

Unknown — onboarding: unknown, pricing: unknown, trial: no (confidence: low).

## Security (1)

- **Transition Bio Domain Security** — TLSv1.3 · DMARC

## Tags

Company, Biotechnology, Drug Discovery, Life Sciences, Machine-Learning, Artificial Intelligence, Microfluidics, Proteomics, Therapeutics, Neurodegeneration

---

Profiled by [API Evangelist](https://apievangelist.com) and published on [APIs.io](https://apis.io/providers/transition-bio/). Scores are computed from the provider's own public artifacts under a published rubric.